WIRB 20140979
#14346776.0

It Starts With You!

Join the research effort for
ENDOGENOUS CUSHING'S SYNDROME.

Consider the SONICS study.

sonics™

Now seeking volunteers to participate in a clinical study for an investigational drug, levoketoconazole (COR-003).

Talk to your doctor to learn more about the SONICS study. You can also go to **www.cushingssyndromestudy.com** for more information.

WHAT IS ENDOGENOUS CUSHING'S SYNDROME?

Endogenous Cushing's syndrome occurs when the body produces too much cortisol and therefore is exposed to continuously high levels of cortisol. Most forms of endogenous Cushing's syndrome are caused by tumors in the pituitary gland, others by tumors in the adrenal glands, or in other places throughout the body (ectopic tumors).

WHAT IS THE PURPOSE OF THE STUDY?

The purpose of this study is to test the effects and safety of COR-003 on people with endogenous Cushing's syndrome. The safety and efficacy of COR-003 for treatment of endogenous Cushing's syndrome have not been established.

WHAT KIND OF STUDY IS IT?

This study is open-label. This means that both the health care providers and the study participants are aware of the treatment being given. In this study, everyone will receive levoketoconazole (COR-003) for the duration of the study.

WHAT DOES THE STUDY INVOLVE?

Eligible participants will start taking doses of levoketoconazole (COR-003) by mouth in tablet form. Your doctor will increase the dose slowly and see how well you respond. Once your doctor determines that you have responded, then you will take that dose for 6 months. You will then continue in the study for an additional 6 months at the same dose or a dose determined by the study doctor. In total, participants can expect to be followed for over a year.

Throughout the study, participants can expect to meet regularly with a study doctor and take part in a variety of medical tests to make sure they are doing well. The doctor will test how well the medication is working—and make adjustments if necessary—primarily by measuring the cortisol levels in urine. The doctor will also take other health measures such as blood pressure, weight, glucose levels in blood, etc.

Because this study is also being done to learn more about possible side effects, participants will need to let the doctor know about changes in their usual health.

WHO IS ELIGIBLE?

The study is for adults (18 years or older) with a diagnosis of endogenous Cushing's syndrome confirmed by your doctor. A doctor participating in the study can talk to you about whether or not you are eligible. If you would like to be considered for the study, please talk to your doctor or visit **www.cushingssyndromestudy.com** and fill out the form.

ABOUT STRONGBRIDGE BIOPHARMA

Strongbridge Biopharma is a biopharmaceutical company focused on the development and commercialization of novel therapeutic options to help bridge treatment gaps for patients with rare diseases. Cortendo AB is a Strongbridge Biopharma company and the sponsor of the COR-003 SONICS trial. This means Cortendo planned and organized this study, and will also collect and analyze the data from the study.

STRONGBRIDGE
BIOPHARMA

www.cushingssyndromestudy.com
www.strongbridgebio.com

Cortendo AB is a Strongbridge Biopharma company and the sponsor of the COR-003 SONICS trial.

MLR007 01/2016 V1